Stockholm, Sweden, June 20, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the appointment of Sara Melton as President of North America. Ms. Melton will be part of the Company’s leadership team and brings over 20 years of commercial leadership experience in biotechnology, pharmaceutical, and medical device companies, including rare disease. She will be responsible for establishing and maintaining a successful presence of Egetis and its products in the United States and Canada, including building the infrastructure for Egetis North America, developing relationships with key national stakeholders, and recruiting a highly effective team to support all initiatives necessary for the successful launch of Emcitate in 2024.
Nicklas Westerholm, CEO of Egetis, commented: “Sara has an impressive track record of success in commercial leadership including launching companies and medicines for rare diseases. I am delighted to welcome her to our team at Egetis. Sara will be responsible for initiating the establishment of a commercial infrastructure in the US for Emcitate. We are on track to submit a New Drug Application for Emcitate to the FDA in mid-2023.”
Henrik Krook, VP Commercial Operations of Egetis, continued: “I am very pleased to welcome Sara to the Egetis team for the important work of ensuring successful preparations for the anticipated launch of Emcitate in the US in 2024. With her demonstrated patient focus and strong leadership skills, I am confident that impactful initiatives, such as disease awareness campaigns, diagnosis pathways and access routes, will be implemented to improve the situation for those affected by MCT8 deficiency.”
Prior to joining Egetis Ms. Melton served as Vice President Commercial, Sales and Marketing Rare Disease at Mezzion Pharmaceuticals, Chicago, IL. Sara previously held various commercial leadership roles in biotechnology, pharmaceutical and medtech companies, including Astellas US LLC., Bristol-Myers Squibb, Arthrex Inc., and Achaogen Inc. Ms. Melton has an EMBA from Northwestern University, Kellogg School of Management.
Sara Melton, President North America, said: “MCT8 deficiency is a devastating disease for patients and their caregivers. I look forward to working with the passionate team at Egetis to design and execute a successful commercial strategy in the US for Emcitate and ensure a successful long-term presence of Egetis and its future products in North America.”
